Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV  by McGregor, A. et al.
Virology 410 (2011) 76–87
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roGuinea pig cytomegalovirus GP84 is a functional homolog of the human
cytomegalovirus (HCMV) UL84 gene that can complement for the loss of
UL84 in a chimeric HCMV
A. McGregor ⁎, K.Y. Choi, M.R. Schleiss
Center for Infectious Diseases and Microbiology, Translational Research and Division of Infectious Diseases, University of Minnesota Medical School, Department of Pediatrics,
2001 Sixth Street SE, Minneapolis, MN 55455, USA⁎ Corresponding author. Fax: +1 612 624 8927.
E-mail address: mcgre077@umn.edu (A. McGregor)
0042-6822/$ – see front matter © 2010 Elsevier Inc. Al
doi:10.1016/j.virol.2010.10.028a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 March 2010
Returned to author for revision
23 July 2010
Accepted 15 October 2010
Available online 20 November 2010
Keywords:
Cytomegalovirus
Congenital infection
Bacterial artiﬁcial chromosome (BAC)
pp65
UL84
Transdominant inhibition
Homolog
Chimera
Guinea pig
AntiviralThe guinea pig cytomegalovirus (GPCMV) co-linear gene and potential functional homolog of HCMV UL84
(GP84) was investigated. The GP84 gene had delayed early transcription kinetics and transient expression
studies of GP84 protein (pGP84) demonstrated that it targeted the nucleus and co-localized with the viral
DNA polymerase accessory protein as described for HCMV pUL84. Additionally, pGP84 exhibited a
transdominant inhibitory effect on viral growth as described for HCMV. The inhibitory domain could be
localized to a minimal peptide sequence of 99 aa. Knockout of GP84 generated virus with greatly impaired
growth kinetics. Lastly, the GP84 ORF was capable of complementing for the loss of the UL84 coding sequence
in a chimeric HCMV. Based on this research and previous studies we conclude that GPCMV is similar to HCMV
by encoding single copy co-linear functional homologs of HCMV UL82 (pp71), UL83 (pp65) and UL84 genes..
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Human cytomegalovirus (HCMV) is a ubiquitous pathogen that
causes asymptomatic infection in normal healthy individuals. How-
ever, it has emerged as a serious infection in immune suppressed
individuals, including organ transplant and AIDS patients as well as
the fetus during pregnancy (Pass, 2001). Indeed, congenital infection
of the fetus by HCMV (1–2% of live births in the US) is a major cause of
mental retardation and hearing loss in surviving newborns in the
developed world (Ross and Boppana, 2005; Grifﬁths and Walter,
2005). Although there are candidate vaccines in clinical trials there is
currently no effective vaccine to HCMV (Schleiss and Heineman,
2006). Antivirals are available but these act at late stages of the virus
life cycle and result in the development of resistant strains emerging
during prolonged antiviral therapy (Biron, 2006; Chou, 2008;
McGregor, 2010). Consequently, there is a need for the development
of new vaccine strategies as well as the development of novel antiviralstrategies that act at an earlier stage of the virus life cycle and less
likely to lead to the development of resistant strains of virus.
In human cytomegalovirus (HCMV) the UL82, UL83 and UL84
genes are thought to have evolved from a common ancestor by gene
duplication with subsequent differentiation to fulﬁll unique functions
associated with the virus life cycle (Davison and Stow, 2005). Both
UL82 and UL83 encode tegument proteins whereas UL84 encodes a
non-structural protein (He et al., 1992; Hensel et al., 1992; Schmolke
et al., 1995). Both tegument proteins, pp71 (UL82) and pp65 (UL83),
have roles in initiating the viral life cycle in the infected cell as well as
avoiding the cellular innate immune response (Abate et al., 2004;
Baldick et al., 1997; Cantrell and Bresnahan, 2006). The function of
UL84 protein in the HCMV viral life cycle is not entirely understood
but it has an essential role insofar as knockout HCMV UL84 mutants
are nonviable (Dunn et al., 2003; Xu et al., 2004; Yu et al., 2003). The
UL84 proteins are unique to betaherpesviruses and in HCMV it is
required in an auxiliary role for HCMV DNA replication (Sarisky and
Hayward, 1996; Xu et al., 2004). Speciﬁc interaction of pUL84with the
DNA polymerase accessory protein (pUL44) has been demonstrated
(Strang et al., 2009). However, Reid et al. (2003) using HSV-1 DNA
replication fork proteins showed that replication from the HCMV
origin site is independent of UL84 protein. Initially identiﬁed as a
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cytoplasm and multimerize with itself (Colletti et al., 2004; He et al.,
1992; Lischka et al., 2003; Lischka et al., 2006; Xu et al., 2002). The
purpose of pUL84 shuttling has yet to be deﬁned but involves the
alpha beta importin pathway (Lischka et al., 2003). Potentially,
shuttling may be linked to pUL84 homology with DExD/H box family
of helicases, which shuttle between the nucleus and cytoplasm
(Colletti et al., 2005; Lischka et al., 2006). The protein is also suggested
to have UTPase activity (Colletti et al., 2005) and other pUL84
homologs, including GPCMV, carry UTPase motifs (Davison and Stow,
2005). Additionally, pUL84 exhibits a transdominant inhibitory
growth effect on HCMV and interaction studies determined that the
inhibitory effect is linked to speciﬁc interaction with IE2-p86 that
impairs transactivation (Gebert et al., 1997; Colletti et al., 2004). Since
IE2-p86 is important for the initiation of HCMV viral replication, this
transdominant inhibitory effect could potentially be developed as a
novel antiviral strategy, which would impact on virus replication at an
earlier stage than current antivirals. Therefore in addition to
identifying GPCMV GP84 as a functional homolog we sought to
identify a minimal peptide domain with a transdominant inhibitory
effect on GPCMV growth for potential development as an antiviral in
the guinea pig model.
The strict species speciﬁcity of HCMV precludes studying this virus
in a non-human animal model. Consequently, animal CMVs are used
in their respective hosts for viral pathogenicity or candidate vaccine
studies. Various animal models have been explored in the study of
CMV (Schleiss, 2006; Barry et al., 2006). The guinea pig model of CMV
is uniquely useful for the study of congenital infection and the
development of intervention strategies that prevent infection of the
fetus (Kumar and Nankervis, 1978; Kern, 2006; Schleiss, 2002). One
focus of vaccines against HCMV has been directed towards the pp65
viral tegument protein (UL83), the major CTL target (Gonczol and
Plotkin, 2001). The homolog protein, GP83, in GPCMV has been
successfully used as protective vaccine in the guinea pig model
(McGregor et al., 2004; Schleiss et al., 2007). In contrast, theM84 gene
in murine cytomegalovirus (MCMV), while co-linear to UL84, encodes
a functional homolog to pp65 (UL83) and is a major CTL target (Ye et
al., 2004). Accordingly, M84 vaccines provide protection against
MCMV challenge inmice (Holtappels et al., 2001;Morello et al., 2000).
Hence, from the standpoint of vaccine development studies in the
guinea pig model it was important to more properly deﬁne the
function of the co-linear homolog to UL84, GP84, in the GPCMV life
cycle. We previously identiﬁed proteins encoded by the GPCMV genes
GP82 and GP83 as tegument proteins and direct functional homologs
of HCMV encoded proteins pp71 (UL82) and pp65 (UL83) (McGregor
et al., 2004; Schleiss et al., 1999). Preliminary studies suggest that
the predicted pGP84 is potentially a functional homolog of pUL84
based on the presence of conserved UTPase motifs not found in the
MCMV homolog (Davison and Stow, 2005). Therefore in this paper
we attempted to demonstrate that pGP84 is a functional homolog
of pUL84.
Results
GP84 expression and cellular location of pGP84 protein
The GP84 ORF encodes a protein of 483 aa in length that exhibits
the highest homology to HCMV UL84 protein (22% identity by BLAST
analysis). Analysis of the kinetics of gene expression in wild type virus
infected cells reveals the GP84 gene expression to be delayed early
kinetics (Fig. 1), which is similar to HCMV UL84 (He et al., 1992). This
conclusion is based on comparative RT-PCR assays also performed for
different classes of GPCMV genes previously characterized (Fig. 1):
immediate early, IE2, unique exon GP122 (Yamada et al., 2009); early,
GP54, the viral polymerase (Schleiss, 1995); late, GP83, encoding the
homolog to pp65 (Schleiss et al., 1999). Additionally, the class ofkinetics was also conﬁrmed by the inclusion of protein inhibitor
cycloheximide (for IE transcripts) or DNA replication inhibitor
phosphonoacetic acid, PAA (for detection of IE and E transcripts) in
virus infected cultures. GP84 transcripts were detected in the
presence of PAA but not in the presence of cycloheximide which
conﬁrmed GP84 as an E transcript (see supplementary Figure S1).
The full length GP84 ORF was cloned in frame into the expression
vector pCMV2A (Promega), which tagged the N-terminal domain of
the ORF with an epitope FLAG tag. Transient expression studies of
pGP84 were carried out on GPL cells. The cellular distribution of
pGP84 was determined at various times between 3 and 48 h post
transfection via immunoﬂuorescence assay. Fig. 1(ii), image A,
indicates that pGP84 is a nuclear protein and this result is consistent
with the cellular location reported for HCMV pUL84 (Xu et al., 2002).
Using convenient restriction enzyme sites a series of collapses were
made to the full length GP84 ORF to generate N- and C-terminal
deletions as described in Materials and methods (and shown in
Supplementary Figure S2). In transient cellular expression assays, the
N-terminal collapsed pGP84 (lacking the ﬁrst 211 aa of full length
pGP84) encoded on plasmid pFLAGGP84(B) appeared only in the
cytoplasm and not in the nucleus (Fig. 1(ii), image C). In contrast, the
C-terminal and combined N- and C-terminal truncated versions of
pGP84 (encoded on plasmids pFLAGGP84(S) and pFLAGGP84(B)
respectively) were found in both nuclear and cytoplasmic compart-
ments (Supplementary Figure S3). This indicated that pGP84 carries a
N-terminal NLS as described for HCMV pUL84 (Xu et al., 2002).
However, further study would be required to determine if pGP84 is
dependent upon the alpha and beta importin pathway for nuclear
targeting as described for HCMV (Lischka et al., 2006).
pGP84 co-localizes with the viral DNA polymerase accessory protein
(pGP44)
HCMV pUL84 plays an accessory role in viral DNA replication and
has recently been shown to interact with the viral DNA polymerase
accessory protein, pUL44, (Strang et al., 2009). The UL44 homolog
gene (GP44) inGPCMV (Schleiss et al., 2008) encodes a protein of 407
amino acids that exhibits 57% identity with HCMV pUL44 by BLAST
analysis (McGregor, unpublished data). In an effort to demonstrate
similar interactions between GPCMV homolog proteins (pGP84 and
pGP44) the GP44 coding sequence was cloned in frame into a FLAG
tag expression plasmid to epitope tag the GP44 ORF. Transient
expression studies were carried out in the presence of GFP tagged
pGP84 expression plasmid or control GFP plasmids (expressing GFP
only or a HCMV pp65 GFP fusion). Interactions were followed by
cellular co-localization studies via immunoﬂuorescence assay. Fig. 2,
panels A–F, show the co-localization of pGP84 and pGP44 in the
nucleus of cells expressing both proteins. Identical patterns of
nuclear aggregates were observed under GFP ﬁlter for pGP84 (panels
A and D) or Texas red ﬁlter for pGP44 (panels B and E). Co-expression
of pGP44 and GFP protein did not indicate any speciﬁc co-localization
(Fig. 2, panels J and K). TheGFP proteinwas seen evenly distributed in
both nuclear and cytoplasmic compartments, whereas pGP44 was
only located in the nucleus and was uniform in the nucleus without
aggregates seen in the presence of pGP84. In another control
experiment, co-expression of pGP44 with HCMV pp65-GFP fusion
protein did not give rise to pGP44 nuclear aggregates (Fig. 2, panels G
and H). The pp65 protein produced characteristic punctate nuclear
ﬂuorescence but the pGP44 protein was evenly distributed in the
nucleus. The expression pattern of pGP44 only (Fig. 2, panel M) is the
same pattern seen in GFP and GFP-pp65 co-transfection cells (K and
H respectively). Overall the transient GP84 expression studies
suggest that the pGP84 has similar cell localization properties to
pUL84 and potentially interacts with the viral DNA replication
machinery as demonstrated for HCMV pUL84 (Strang et al., 2009;
Sarisky and Hayward, 1996).
Fig. 1. Expression studies of GP84. 1(i) RT-PCR assay of GP84mRNA expression in virus infected cells. Wild type virus infected GPL cells (moi=3 pfu/cell) were harvested at different
time points for RNA extraction and mRNA analysis by RT-PCR using GP84, GP54 (viral polymerase), GP122 (IE2 unique exon) and cellular GAPDH speciﬁc primers as described in
Materials and methods. Viral gene classes: immediate early, IE2, unique exon GP122 (Yamada et al., 2009); early, viral polymerase GP54 (Schleiss, 1995); and late, GP83, encoding
pp65 homolog (Schleiss et al., 1999). RT-PCR products were analyzed by agarose gel electrophoresis: GP84 (gel A); GP54 (B); GP122 (C); GP83 (D); GAPDH control (E). In all gels
lanes are as the same. 100 bp ladder (NEB) followed by mock infected cells (mi), time samples 2–48 h post infection (hpi) and no template control (ntc). Time samples 2, 4, 8, 16, 24
and 48 h post infection. 1(ii) Transient expression studies of full length and N-terminal truncated GP84. Immunoﬂuorescence assay of FLAG-tagged GP84 protein transiently
expressed in GPL cells transfected with pFLAGGP84 or pFLAGGP84(B). Assay performed at 10 h post transfection. Primary antibody anti-FLAG and secondary antibody anti-mouse
IgG conjugated to FITC (images A and C). Cells counterstained with DAPI (images B and D). Arrow indicates same cell under FITC and DAPI ﬁlters. Images A and B, full length pGP84
(pFLAGGP84 plasmid). Images C and D, N-terminal truncated pGP84 (pFLAGGP84(B) plasmid).
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Fig. 2. Co-localization studies of transiently expressed pGP84 and pGP44. Transient plasmid expression assay of FLAG-tagged pGP44 (pFLAGGP44 plasmid) in the presence of GFP
tagged vectors: GFP tagged pGP84 (images A–F); GFP tagged pp65 (G–I); GFP control (J–L). Images M and N correspond to transient expression of pGP44 only cells. pGP44 detected
by anti-FLAG primary antibody and secondary antibody anti-mouse IgG conjugated to TRITC. pGP44 images B, E, H and M. Cells counterstained with DAPI to identify cell nucleus
(right column). Image A and D, pGP84 expressed as N-terminal tagged GFP protein (pGFPGP84). Image G, pGFPpp65 (HCMV pp65N-terminal GFP tagged). Image J, control GFP
plasmid pGFP-C1 (Clontech). Protein cellular localization determined at 12 h post transfection as described in Materials and methods.
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Gebert et al. (1997) demonstrated that over expression of pUL84
in a human cell line resulted in subsequent impairment of HCMV
growth, indicating that pUL84 has a transdominant inhibitory effect
on HCMVwhen over expressed under HCMV IE promoter control. The
speciﬁc interaction of pUL84 with the immediate early transactivation
protein IE2 is the basis for the inhibitory effect (Gebert et al., 1997). A
GPCMV homolog to IE2 has recently been identiﬁed with the encoded
protein sequence in the unique GPCMV IE2 exon (GP122) showing
62% identity to HCMV pUL122 (McGregor, 2010; Schleiss et al., 2008;
Yamada et al., 2009). Therefore it seemed probable that a similar
transdominant inhibitory effect for GPCMV could be demonstrated.
Two transdominant inhibitory GPCMV growth assays were devel-
oped. In the ﬁrst assay, infectious GPCMV BAC DNA (McGregor and
Schleiss, 2001) was co-transfected onto conﬂuent monolayers of GPL
cells in the presence or absence of GP84 expression plasmids or
control plasmids. Virus development was allowed to proceed for a
similar length of time and ﬁnal viral titers from individual wells
determined at the end of the experiment (day 18). During theexperiment GFP positive transfected cells, GPCMV replication and
viral spread could easily be followed in real time by virtue of the GFP
gene incorporated into the GPCMV genome. Transfection of the
GPCMV BAC DNA by itself or with the empty expression vector
resulted in rapid generation of viral plaques and GFP viral spread
across the monolayer (Fig. 3, panels A and C). The presence of the
empty expression vector (pCMV2A) did not affect the development of
viral spread and only slightly impaired viral yield, 1.5×106 pfu/ml in
the absence of pCMV2A (empty vector) compared to 1.4×106 pfu/ml
in the presence of pCMV2A. In contrast, co-transfection of GPCMV BAC
DNA with the GP84 expression vector (pFLAGGP84) severely
impaired development of virus and viral spread across the monolayer
(Fig. 3, panel B) with an average virus yield of 1×102 pfu/ml. N-
terminal or C-terminal truncated versions of GP84 were equally as
effective at inhibiting GPCMV virus growth (average virus yield
1×102 pfu/ml). Surprisingly, the double truncated N- and C-terminal
GP84 collapse that encodes 99 aa (codons 212–311) of pGP84
sequence (pFLAGGP84BS) was equally capable of inhibiting GPCMV
(average virus yield 1× 102 pfu/ml) as full length pGP84
(pFLAGGP84), Fig. 3 (image B and D). The use of VP16 (HSV-1) or
GP83 (GPCMV pp65 homolog) expression plasmids (McGregor et al.,
Fig. 3. GPCMV pGP84 transdominant growth inhibition assay. GFP tagged GPCMV BAC DNA was transfected onto GPL cells alone or co-transfected with GP84 expression vectors
(pFLAGGP84 or pFLAGGP84BS) or empty expression vector (pCMV2A). Development of viral plaques could be detected by GFP reporter gene expression in infected cells. Viral spread
was monitored between 7 and 18 days post transfection. At day 18 all wells were harvested and viral titer determined. Data shown is representative GFP virus spread in wells of a six
well dish at 16 days post transfection. Images: GPCMV BAC DNA only well, panel A; GPCMV BAC DNA plus empty vector (pCMV2A), panel C; B. GPCMV BAC DNA plus pFLAGGP84
(full length pGP84), panel B; GPCMV BAC DNA plus pFLAGGP84BS (truncated pGP84), panel D. Virus inhibition was obtained in the presence of full length or truncated pGP84
(images B and D).
Table 1
Transdominant inhibitory effect on GPCMV growth by the pGP84 minimal inhibitory
domain expressed by permanently transduced cell. Input virus infection is indicated
and ﬁnal virus yield determined by titration of infected cells at a set time point post
infection as described in Materials and methods. GPL-GFP, control cells expressing GFP.
GPL-GFPGP84ID, cells expressing the pGP84 99 aa inhibitory domain fused to the C-
terminal of GFP.
Input GPCMV (pfu/cell) Viral titer GFP cells Viral titer GFPGP84ID cells
0.1 2.5×106 pfu/ml 3×104 pfu/ml
0.01 1×106 4×103
0.001 2×106 5×103
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empty vector (1.2×106 pfu/ml and 1.3×106 pfu/ml respectively) and
had no effect on virus growth. These results indicate that pGP84 has a
transdominant inhibitory activity against GPCMV similar to that
described for pUL84 against HCMV (Gebert et al., 1997). Overall the
pGP84 transdominant inhibitory assay impaired virus yield by
approximately 10,000 fold. However, only a small 99 aa domain
(codons 212–311) would appear to be sufﬁcient for inhibitory growth
effect. A similar minimal inhibitory domain has not been identiﬁed for
pUL84.
The GPCMV BAC based transdominant inhibitory assay did not
demonstrate a direct inhibitory effect on live virus infection as virus
was derived from GPCMV BAC transfected cells. Consequently, a
second inhibitory growth assay was developed that tested the ability
of pGP84 to impair live GPCMV infection of GPL cells. Initially GPL cell
lines were established that expressed the pGP84 minimal inhibitory
domain fused to the C-terminal domain of GFP (pEGFP-C1) as
described in Materials and methods. As a control, GPL cell lines
were established that only expressed GFP. Clonal cell lines were
designated GPL-GFPGP84ID and GPL-GFP respectively and were
tested for their ability to inhibit virus growth at different input virus
moi. The pGP84 inhibitory effect on virus growth was most
pronounced at the lowest moi (0.001–0.01 pfu/cell) with a 3 log
drop in virus yield in comparison to the equivalent infection on
control GPL-GFP cells (Table 1). The results demonstrate that the
minimal pGP84 inhibitory domain when expressed in trans was
effective at inhibiting live virus infection and veriﬁes the results seen
in the initial inhibitory assay. The pGP84 inhibitory effect was speciﬁc
to GPCMV as no viral inhibition was seen with HSV-1 (data not
shown). In HCMV the transdominant effect is thought to occur by
pUL84 interacting with IE2-p86 to inhibit transactivation of early
genes by IE2 protein (Gebert et al., 1997). Although a homolog to IE2
protein has recently been identiﬁed in GPCMV (Schleiss et al., 2008;Yamada et al., 2009) further studies are required to characterize the
IE2 transactivation function as well as IE2 protein–protein
interactions.
Targeted knockout of GP84 in GPCMV
In HCMV the UL84 gene is essential for virus replication (Dunn et al.,
2003; Xu et al., 2004; Yu et al., 2003). We sought to determine the
essential nature of GP84 by speciﬁc gene knockout in an infectious
GPCMV BAC (McGregor and Schleiss, 2001). An insertion deletion was
introduced into the GP84 ORF by the insertion of a kanamycin cassette
between two BamH I sites close to the start of the GP84 ORF in a GP84
shuttle vector for targeted knockout of GP84. Fig. 4(i), shows the
location of the GP84 gene knockout on the GPCMV genome. Full length
mutant GPCMV BACs were screened by Hind III restriction proﬁle
analysis with the correct insertion of the Km cassette resulting in the
disruption of the GPCMV Hind III ‘A’ band, co-ordinates 103,313–
147,381 bp, (Schleiss et al., 2008; Gao and Isom, 1984). Fig. 4(ii) shows
the modiﬁed restriction pattern of the GP84 GPCMV BAC mutant under
Hind III restriction enzymeproﬁle analysis. ThemodiﬁedGP84 locuswas
further veriﬁed by PCR analysis using commonPCR primers ﬂanking the
Fig. 4. Characterization of GP84 knockout GPCMVmutant (GP84d). (i) GPCMV genomemap of Hind III sites and the location of the knockout GP84 gene. Shown is the GPCMV Hind III
‘A’ locus (co-ordinates 103,314–147,381 bases) encoding GP84 CDS (complement 133,286–134,737 bases). Insertion of a kanamycin resistance cassette into the GP84 coding
sequence between two BamH I sites (134,097 and 134,314 bases) results in an insertion deletion disruption of the GP84 coding sequence. (ii) Wild type and GP84 mutant GPCMV
BAC Hind III restriction proﬁle analysis. Agarose gel of the DNA restriction proﬁle analysis of mutant and wild type GPCMV BACs. Lanes: 1. kb ladder (NEB). 2. wt GPCMV BAC; 3.
GP84d GPCMV BAC. Insertion of a kanamycin cassette into the GP84 gene introduces a new Hind III site into the GPCMV genome and disrupts the Hind III ‘A’ band encoding the GP84
gene. Full length (lane 2) and modiﬁed bands encoding part of the Hind III ‘A’ band (lane 3) are indicated with circles. (iii) GPCMV BAC diagnostic PCR analysis of the GP84 locus.
Common primers ﬂanking the site of modiﬁcation in the GP84 locus were used to verify the modiﬁcation to the GP84 locus in comparison to the wild type locus. Shown is an agarose
gel of GP84 PCR products from different BAC DNA templates. Lanes: 1. wt GPCMV BAC; 2. GP84d GPCMV BAC mutant. Shift in the size of the locus conﬁrms correct insertion of the
kanamycin cassette plus deletion of GP84 sequence between BamH I sites. (iv) Viral DNA diagnostic PCR analysis of the GP84 locus. Common diagnostic GP84 locus primers were
used to conﬁrm the status of the GP84 locus in viral genomes: 1. wt GPCMV; 2. GP84dmutant; 3. GP84d rescue virus. Themutant virus retains the samemodiﬁcation generated in the
GPCMV BAC mutant and the rescue virus has a wild type sized GP84 locus. (v) Multi-step growth curve of GPCMV GP84 mutant (GP84d). Growth curve performed as described in
Materials andmethods. GPCMV GP84 knockout mutant (GP84d) was compared towild type GPCMV (wt) and GP84d rescue virus (GP84R). Input virus moi was 0.1 pfu/cell with time
points taken at 24 h. intervals between 0 and 6 days post infection.
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BAC DNA veriﬁed the GP84 locus was correctly modiﬁed by insertion of
a Kmcassette and small deletion to the GP84 coding sequence, see Fig. 4
(iii). Transfection of the GP84 mutant GPCMV BAC onto GPL cells
resulted in the generation of infectious virus, designated vGP84d. PCR
analysis of viral DNA conﬁrmed that the mutant GP84 locus was
retained in the virus unless rescued back to wild type, see Fig. 4(iv). A
multi-step growth curve of vGP84d, Fig. 4(iv), demonstrated that
vGP84d had impaired growth kinetics in comparison to wild type virus,
or rescue virus (GP84R). Additionally, the mutant produced greatly
enlarged cells in comparison to wild type virus (data not shown). The
ability to generate a viable GP84 knockout virus contrasts with anabsolute requirement for UL84 to generate viable HCMV (Dunn et al.,
2003; Yu et al., 2003; Xu et al., 2002). However, there is a greater level of
impairment associated with a GP84 knockout in comparison to
knockout of the co-linear UL84 gene homolog in MCMV (M84), which
does not exhibit any impaired growth kinetics in tissue culture (Morello
et al., 1999).
Substitution of GP84 in place of UL84 in a chimeric HCMV
In an ultimate test of similarity of function between UL84 and
GP84 we sought to determine if the GP84 coding sequence could
functionally replace the UL84 coding sequence in a chimeric HCMV.
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et al., 2003). Two types of UL84 HCMV mutants were generated: a
UL84 deletion mutant (HCMV::UL84d); and a GP84 chimeric HCMV,Fig. 5. Generation and characterization of GP84 chimeric HCMV. (i) Overall strategy for the ge
knockout shuttle vectors. UL84 ﬂanking sequence was generated by PCR (right arm left arm,
vector to generate pUL84d. For generation of the GP84 chimeric HCMV the FLAG-tagged G
plasmid pUL84d to generate construct pUL84d/GP84. Shuttle vectors were linearized by Pac
described by McGregor et al. (2004). Structure of GP84 HCMV chimeric virus is shown in t
(A) HCMV BAC DNA Hind III restriction proﬁles. Lanes: 1. wt HCMV BAC DNA; 2. UL84 delet
modiﬁed 7.8 kbHind III subgenomic fragment (co-ordinates 120,817–128,615 HCMV Towne)
of the UL84 coding sequence and insertion of a Km cassette (UL84 deletionmutant HCMV BAC
3). (B) PCR analysis of wild type and mutant UL84 loci from HCMV BAC clones. Common PC
products were analyzed by agarose gel electrophoresis. Lane: 1. GP84 chimeric HCMV BAC;
mutant UL84 loci from viral DNA. Common PCR primers ampliﬁed the modiﬁed UL84 locus f
agarose gel electrophoresis. Note that the rescue virus was generated to the lethal UL84 kno
Diagnostic PCR conﬁrms that the chimeric virus encodes a modiﬁed UL84 locus similar to th
(Towne) and GP84 chimeric HCMV. Growth curve carried out as described in Materials and
every 12 h (0–90 h post infection) as described in Materials and methods. (iv) Western blot
infected HFF cells; (2) GP84 chimeric virus infected cells; (3) HCMV (Towne) infected cells.
FLAG and secondary anti-mouse IgG conjugated to HRP as described in Materials and methencoding GP84 in place of UL84 (HCMV::GP84). A shuttle vector was
generated for the UL84 locus for targeted modiﬁcations as described
in Materials and methods and is summarized in Fig. 5(i). Forneration of UL84 knockout and GP84 chimera HCMV BACmutants. Construction of UL84
A and B). For UL84 deletion HCMV BAC a BamH I Km cassette was cloned into the shuttle
P84 ORF from pFLAGGP84 was PCR cloned as a Bgl II cassette 5′ to the Km cassette in
I digestion prior to recombination in bacteria with HCMV Towne BAC following protocol
he bottom of the ﬁgure. (ii). Analysis of HCMV wild type and UL84 mutant structures.
ion mutant HCMV BAC DNA; 3. GP84 chimera HCMV BAC DNA. Dots mark wild type or
encoding the UL84wild type locus (lane 1) andmodiﬁed by the deletion of themajority
, lane 2) plus the insertion of the GP84 coding sequence (GP84 HCMV chimera BAC, lane
R primers ampliﬁed the modiﬁed UL84 locus from the HCMV BAC constructs and PCR
2. wild type HCMV BAC; 3. UL84 deletion HCMV BAC. (C) PCR analysis of wild type and
rom wild type and GP84 chimeric HCMV viral DNA and PCR products were analyzed by
ckout. Lane: 1. wild type HCMV; 2. GP84 HCMV chimera; 3. UL84 deletion rescue virus.
e GP84 HCMV chimeric BAC (B, lane 1). (iii) One step growth curve of wild type HCMV
methods with an initial input of virus of 3 pfu/cell (moi) with time point samples taken
of FLAG-tagged GP84 protein expressed in chimeric virus infected cells. Lanes: (1) Mock
Protein ladder (Invitrogen). GP84 protein detected with primary antibody mouse anti-
ods.
Fig. 5 (continued).
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cloned into the pUL84d shuttle vector to generate pUL84d/GP84,
which placed the GP84 ORF under UL84 promoter control. In separate
recombination reactions the linearized plasmid DNA (pUL84d or
pUL84d/GP84) was electroporated into recombination induced
DH10B bacteria carrying the HCMV (Towne strain) BAC. Full length
HCMV mutants (HCMV::UL84d or HCMV::GP84 BACs) were isolated
and screened by Hind III restriction digestion to verify modiﬁcation of
the 7.8 kb subgenomic Hind III fragment (HCMV Towne co-ordinate
nucleotides 120,817–128,615) predicted to encode UL84. Fig. 5(ii)A
shows the modiﬁcations to the UL84 locus, which were a result of the
introduction of a novel Hind III site present in the Km cassette. The
deletion mutant removes the majority of the UL84 coding sequence
(codons 59–401) but introduces a Km cassette. The chimera removes
the majority of the UL84 coding sequence and introduces the GP84
ORF and a Km cassette. The modiﬁcations to the UL84 locus were
further veriﬁed by diagnostic PCR using common primers ﬂanking the
modiﬁed UL84 locus which conﬁrmed the speciﬁc modiﬁcations to
the UL84 locus, see Fig. 5(ii)B.
Two independent HCMV BAC clones for each mutant were
transfected separately onto HFF cells to generate virus. Despite
repeated transfections of the UL84 deletion knockout HCMV BAC DNA
(HCMV::UL84d) no virus was generated. This conﬁrmed the essential
nature of the UL84 gene. The lethal UL84 knockout could be rescued
by co-transfection of the HCMV::UL84d BACmutant with a rescue PCR
product (3.7 kb fragment) encoding the wild type UL83-UL85 locus to
generate virus (see Material and methods). The chimeric HCMV BAC
encoding GP84 (HCMV::GP84) generated viable virus, designated
HCMV::GP84. A one step growth curve of HCMV::GP84 indicated that
the chimera grewwith similar kinetics to wild type HCMV (Towne) on
HFF cells, see Fig. 5(iii). Expression of FLAG-tagged GP84 protein in
chimeric HCMV infected HFF cells was conﬁrmed by Western blot of
infected cell lysate which detected a band of approximately 70 kDa,
the predicted size of the GP84 protein, see Fig. 5(iv). This datasuggests that GP84 can functionally replace the loss of UL84 in a
chimeric HCMV and provides the strongest evidence that GP84 is a
functional homolog of UL84.
Discussion
In conclusion our studies on GP84 protein demonstrate that it is
most likely the functional homolog of pUL84 in GPCMV as it shares a
number of common features with pUL84. Furthermore, the GP84
ORF can substitute for the loss of the essential UL84 coding sequence
in a chimeric HCMV. Further studies are required to characterize the
pGP84 NLS and the interactions of pGP84 with the GPCMV IE2
homolog. Preliminary studies indicate that the pGP84 NLS cannot be
easily transplanted to another protein by the simple grafting of only
the N-terminal domain to a reporter gene (McGregor, unpublished
data). This suggests that the pGP84 carries a more complex bipartite
NLS as described for HCMV pUL84 (Lischka et al., 2006). Analysis of
the GPCMV IE2 unique exon GP122 indicates that it has high
homology with HCMV UL122 exon, which suggests that GPCMV IE2
may function in a similar manner to HCMV IE2. However, no
transactivation studies have been performed with the full length IE2
protein. Previous success has been achieved for analysis of
transactivation activity associated with the GPCMV pp71 homolog,
encoded in GP82 (McGregor et al., 2004). Additionally, the GPCMV
genome has recently been fully sequenced (Schleiss et al., 2008;
Yamada et al., 2009), which should allow the development of
suitable IE2 transactivation/pGP84 interference assays. Since pUL84
is linked to virus replication it is curious that a MCMVM84mutant is
not impaired in tissue culture. This result certainly confuses the issue
of MCMV being the primary animal model for pathogenicity and
vaccine strategies against CMV. However, the GPCMV model is not a
perfect substitute. The GP84 knockout mutant was capable of
generating viable virus despite it being impaired. Possibly rodent
CMVs have evolved a DNA replication strategy that is more
dependent upon a cellular protein rather than the viral pUL84
homolog. Reid et al. (2003) have demonstrated HCMV origin
dependent DNA replication in the absence of pUL84, which supports
an alternative DNA replication strategy not dependent on pUL84.
This area awaits further investigation. The transient expression
protein localization studies were performed with FLAG epitope and
GFP tagged ORFs. This is a common strategy to study protein cellular
localization in the absence of speciﬁc antibodies to the respective
protein(s). Similar results were obtained for the same protein
(pGP84 and pGP44) under both GFP or FLAG tagging and it is
therefore unlikely that these tags contributed to cellular localization
patterns. However, ideally future pGP84 studies should additionally
employ protein speciﬁc antibodies as well as the continued use of
FLAG or GFP tagged constructs.
In HCMV, the UL83 protein, pp65, is the protective T cell target and
not pUL84 (Wills et al., 1996). In MCMV the co-linear homolog gene to
UL84, M84, encodes the protective T cell target antigen but not the
UL83 homolog, M83 (Morello et al., 1999; Ye et al., 2004). It was
important to deﬁne GP84 as a functional homolog of UL84 as this has
direct implications for the development of CMV candidate vaccines in
the guinea model. Our results demonstrate the potential problem
associated with the study of species speciﬁc animal CMV in vaccine
studies and necessitates the functional deﬁnition of homolog proteins
in addition to their use as candidate vaccine targets. In earlier studies
we had identiﬁed pGP83 as encoding a tegument protein with
properties similar to HCMV pp65 that acted as a protective T cell
target antigen (Schleiss et al., 1999; McGregor et al., 2004; Schleiss et
al., 2007). The immune response to pGP84 is unknown but does not
seem to be as dominant as the T cell response to pGP83 in wild type
virus infected animals (Schleiss et al., 2007). Therefore pGP84 is not
likely to be a good vaccine target antigen as is the case for HCMV
pUL84. Presumably, identiﬁcation of pGP84 as a functional homolog to
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animal model or the development of novel pUL84 based antiviral
strategies in the guinea pig model.
Antivirals against HCMV are an important concern due to the
development of resistant strains under current antiviral therapies
(Biron, 2006). The ﬁnding that pGP84 has a transdominant inhibitory
effect on viral growth, as does pUL84 on HCMV, is of potential interest
from the standpoint of development of a novel antiviral drug strategy
that could be tested in the guinea pig model. The ability to minimize
the pGP84 inhibitory domain to 99 aa, or perhaps even smaller, could
allow the future development of novel compounds that mimic this
domain and which are also inhibitory towards the virus (Robinson et
al., 2008). Potentially, an antiviral that inhibits IE2 protein could be
more successful in combating CMV infection rather than current
antivirals that inhibit late stages of the virus life cycle (Biron, 2006;
McGregor, 2010) and allow emergence of resistant strains. Antiviral
peptide strategies have been demonstrated to be effective against
herpesvirus infections (Loregian et al., 2005). However, the further
development an antiviral strategy in GPCMV awaits characterization
of pGP84/IE2 of homolog protein interactions. Stamminger and
colleagues recently tested the ability of a peptide aptamer antiviral
that targets the NLS of pUL84 (Kaiser et al., 2009). This could also be
investigated in GPCMV but would ﬁrst require further characteriza-
tion of the pGP84 NLS.
Previously, in our attempts to increase the relevance of the GPCMV
antiviral model we successfully generated a chimeric GPCMV
encoding HCMV UL97 in place of the homolog gene GP97. This
chimeric virus grew with wild type kinetics and was viable in vivo
(McGregor et al., 2008; 2010). The generation of a viable HCMV
chimera encoding GP84 in place of the essential UL84 is a reverse
approach that also demonstrates similarity of gene function between
GPCMV and HCMV. In conclusion, our ﬁndings on GPCMV GP84 and
our previous studies on GP83 indicate a divergence of functions
between co-linear homologs to UL83 and UL84 in MCMV and GPCMV.
In GPCMV the co-linear homologs appear to strictly retain function
similar to HCMV but in MCMV these functions are less conserved and
appear to be shared between both proteins. Overall, these results in
conjunction with our previous studies on GP83 and GP82, encoding
homologs to pp65 and pp71 respectively, further increases the
signiﬁcance of the GPCMV animal model for pathogenicity, vaccine
and antiviral studies.
Materials and methods
Cells, viruses and oligonucleotides
GPCMV (strain 22122, ATCC VR682), GPCMV BAC derived mutant
virus, and vAM403, a green ﬂuorescent protein (GFP) tagged wild
type GPCMV (McGregor and Schleiss, 2001) were propagated on
guinea pig ﬁbroblast lung cells (GPL; ATCC CCL 158) as previously
described (McGregor et al., 2004). HCMV was propagated on human
foreskin ﬁbroblast cells in DMEM (Gibco-BRL) with 10% FCS
supplemented with 1× anti–anti (Invitrogen). Virus titrations were
carried out on six well plates. Plaques were stained with 10% Giemsa
stain or visualized by ﬂuorescence microscopy. All oligonucleotides
were synthesized by Sigma-Genosys (The Woodlands, TX).
Cloning of GPCMV GP84 and generation of GP84 expression vectors and
GP84 knockout shuttle vector
The full length GP84 ORF was PCR cloned from GPCMV viral DNA
as a EcoR I/Hind III fragment into plasmid pNEB193 (New England
Biolabs) using the PCR primers FGP84Ec (5′ GAATTCGATGATCGAA-
GAGACGGCCGAAC) and RGP84Hd (5 ′ AAGCTTACACG-
GATTTGGGCGCGGGATCGC) to generate pNEBGP84 and sequenced to
verify the GP84 coding sequence. The GP84 ORF was cloned in frameas a EcoR I/Hind III fragment into the expression vector pCMV2A
(Promega) to generate the plasmid pFLAGGP84, expressing the full
length GP84 ORF (483 aa) tagged at the N-terminus with a FLAG
epitope tag. Using convenient restriction enzyme sites (BamH I and
Sal I) a series of collapses were made to the full length GP84 ORF to
generate N- and C-terminal deletions (see supplementary Figure S1).
A Sal I collapse at the 3′ end of the ORF generated a C-terminal
deletion mutant encoding codons 1–311, designated pFLAGGP84(S). A
5′ BamH I collapse generated an in frame deletion at the N-terminus
of the GP84 coding sequence between the FLAG tag and codon 212,
designated pFLAGGP84(B). Collapse of both termini generated
pFLAGGP84(BS). The complete GP84 ORF was also PCR cloned in
frame into the C-terminal polycloning site of pEGFP-C1 (Clontech) as
an EcoR I fragment using the primers FGP84Ec and RGP84Ec
(GAATTCACACGGATTTGGGCGCGGGATCGC). Additionally, a truncated
version of the GP84 coding sequence (codons 170–309) was PCR
cloned in frame into pEGFP-C1 (Clontech) as a Bgl II/Sal I fragment to
generate pGFPGP84ID using the primers FGP84Bg (5′ AGATCTAA-
GAACGGCGACGAGCGACACAGCATC) and RGP84Sal (5′ GTCGACT-
TAGGGCGCCGTCACGATCAAGTG). For generation of a GP84 knockout
shuttle vector the plasmid pNEBGP84 was cut with BamH I to create
an internal deletion in the GP84 coding sequence (codons 140–213).
A kanamycin (Km) cassette was PCR ampliﬁed from pACYC177 (NEB)
using the primers using primers previously described (McGregor
et al., 2004) and cloned into the pNEBGP84 BamH I collapse to
generate the GP84 knockout vector pNEBGP84km(Bm). The GPCMV
DNA polymerase accessory protein, GP44, coding sequence (Schleiss
et al., 2008) was PCR cloned as a BamH I fragment in frame into the
expression vector pCMV2C to FLAG epitope the N-terminus of the
GP44 protein. GP44 PCR was performed using the primers F44BmXh
(5′ GGATCCTCTCGAGCTTCTGCGACGCCGGAGGGTATCG) and R44BmXh
(5′ GGATCCTCGAGTCAGGCGGAACATTTCTGCTTCTTGACGTTAGAC).
Generation of HCMV UL84 knockout shuttle vector and GP84/UL84
chimera shuttle vector
A shuttle vector was generated for the HCMV UL84 locus (UL84 CDS
co-ordinates 157,514–155780c)basedonHCMVTownestrain sequence
(GenBank # AY3151972) for targeted modiﬁcations of the HCMV
(Towne) BAC. Left and right armsofﬂankinghomologyaround theUL84
locus were generated by PCR. Left arm (HCMV Towne co-ordinates
nucleotides 157,671–157,390) and right arm (HCMV Towne co-
ordinates 156,341–155,871) were cloned into the same pUC19 vector
sequentially asEcoR I,BamH IandHind III,BamH I fragments respectively
(see Fig. 5). The primers used for the right arm were FBBRFLKUL84 (5′
GGATCCATAAGATCTCGACCCTTCTTTTCGGACGC) and RHPRFLKUL84 (5′
AAGCTTGCATTAATTAAACAGTCTTGCGGTTCCGTCTCCG). The left arm
primers were FELFLKUL84 (5′ GAATTCGCGACAGCTGGATGACCT-
CATCCGCGAAC) and RBLFLKUL84 (5′ GGATCCGGTCGTGGTGG-
TAGTGGTGGTGGCGAG). This construct deletes the majority of the
UL84 coding sequence (codons 59 to 401) but retained the upstream
UL84 promoter. Unique BamHI and Bgl II sites between the left and right
ﬂanking arms allowed cloning of a Km selection marker (McGregor
et al., 2004) and the GP84 ORF. Insertion of the BamH I Km cassette
generatedplasmidpUL84d for deletionof theUL84 coding sequence. For
generationof the chimeric GP84-HCMV, the FLAG-taggedGP84ORFwas
PCR ampliﬁed from pFLAGGP84 as a Bgl II fragment using primers
FFLAGGP84Bg (5′ AGATCTGCCACCATGGATTACAAGGATGACGACGA-
TAAG) and RGP84BgEcV (5′ AGATCTGATATCTATCTTACACGGATTT-
GGGCGCGGGATCGCTTC) and cloned into a unique Bgl II site in
pUL84d to generate pUL84d/GP84, which placed the GP84 ORF under
UL84 promoter control. The GP84 insertion also introduced a unique
EcoRV site 3′ to the GP84 coding sequence. This allowed the insertion of
a kanamycin cassetteﬂankedbyEcoRV restriction sites (McGregor et al.,
2004) to generate pUL84d/GP84Km (Fig. 4). This construct would be
used to introduce the GP84 ORF into the HCMV Towne BAC.
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An inducible recombination system (ET system) was introduced
into DH10B bacterial cells containing either the GPCMV BAC plasmid
(McGregor and Schleiss, 2001) or the HCMV (Towne) BAC plasmid
(Hahn et al., 2003) using a protocol previously described (McGregor
et al., 2008). For knockout of the UL84 gene the plasmid pUL84d was
linearized by a unique restriction enzyme (Pac I) outside the ﬂanking
homologous region. For generation of the chimeric GP84 HCMV BAC
construct the chimeric shuttle vector pUL84d/GP84km was linearized
by Pac I digestion. Linearized shuttle vector DNA was band isolated
and resuspended at a concentration of 1 μg/ul, and electroporated into
recombination induced HCMV BAC-containing cells in separate
reactions for each mutant. Recombinant bacterial colonies of GPCMV
BAC or HCMVmutants were isolated by chloramphenicol (12.5 μg/ml)
and kanamycin (20 μg/ml) antibiotic selection in LB agar bacterial
Petri dishes. Bacterial plates were initially incubated at 39 °C to
remove the ts ET recombination plasmid (Genebridges). Mutant
GPCMV BAC DNA was analyzed by EcoR I and Hind III restriction
digestion to verify the accuracy of the predicted genome conﬁguration
after mutation (McGregor and Schleiss, 2001). HCMV BAC mutants
were analyzed by Hind III restriction proﬁle analysis. Insertion of the
Km drug resistance cassette into the viral genome introduced a novel
Hind III restriction.
Full length HCMV mutants (HCMV::UL84d or HCMV::GP84 BACs)
were further analyzed at the UL84 locus by diagnostic PCR using
common primers (F84 5′CACTTTCCTCGCCACCACTAC; R84 5′
GTAAAAGCGGCGGTAGATACG) ﬂanking the modiﬁed UL84 locus.
Diagnostic PCR reactions were carried out using conditions described
in McGregor et al. (2008) except the extension time at 72 °C was
modiﬁed based on the size of each gene modiﬁcation (based on an
extension time of 30 s. per 500 bases).
For knockout of the GP84 gene on the GPCMV BAC, the GP84
knockout shuttle vector pNEBGP84km(Bm) was linearized by EcoR I
digestion which cut the plasmid in the polylinker sequence outside
the GP84 coding sequence. DNA was band puriﬁed and 1 μg was
electroporated into an aliquot of ET induced electrocompetent DH10B
cells containing the GPCMV BAC as previously described (McGregor
et al., 2004). GP84 knockout mutant GPCMV BAC colonies were
selected under Km selection and screened by restriction proﬁle
analysis to identify full length mutants. The GP84 gene knockout was
conﬁrmed by comparative PCR analysis between wild type and
mutant GPCMV BACs using common ﬂanking primers FGP84g (5′
GAGATGATCGAAGAGACGGCCGAAC) and RGP84g (5′ GTCTACGCCCA-
TAGCGTCGTAGTCG) to amplify either the complete GP84 gene
(1.4 kb) or the modiﬁed GP84 gene locus (2.1 kb).
Generation of mutant GPCMV, chimeric HCMV and rescue of lethal
HCMV knockout mutant
For generation of recombinant viruses, large-scale BAC DNA was
puriﬁed from E. coli using a Qiagenmaxi plasmid kit. GPCMV BAC DNA
was used to transfect GPL cells in six well dishes using Lipofectamine
2000 (Invitrogen) transfection reagent as previously described
(McGregor et al., 2004). HCMV BAC DNA was transfected onto HFF
cells in six well dishes using supertransfect reagent (Qiagen)
following manufacturer's protocol. Transfections were followed for
at least 3–4 weeks for the production of viral plaques. GPCMV GFP
positive viral plaques were detected via microscopy using an inverted
microscope equipped for GFP ﬂuorescent imaging (McGregor and
Schleiss, 2001). The HCMV BAC did not carry a GFP tag and formation
of viral plaques was followed under bright ﬁeld microscopy. Mutants
were rescued back to wild type phenotype by mutant BAC co-
transfection with the appropriate rescue plasmid (GPCMV GP84d
knockout mutant) or PCR product (HCMV UL84 knockout mutant).
HCMV rescue PCR product (UL83–UL85 PCR product) was generatedby PCR ampliﬁcation of Towne genomic DNA. PCR primers were
generated from AD169 genomic sequence (UL83 forward primer 5′
GTTCATCAACAGGTTACCTGAGATGCT, UL85 reverse primer 5′
GCTGCGCAATATGACGCTGAGGTTGATG). This ampliﬁed a predicted
3.7 kb PCR product (121,003–124,762 AD169 co-ordinates). PCR
product was band puriﬁed and used to rescue lethal HCMV UL84
knockout by co-transfection of PCR product (10 μg) with BAC DNA
(1 μg) per transfection well. Rescued viral plaques were picked and
subject to further rounds of plaque puriﬁcation by limiting dilution.
Viral DNA was extracted from virus infected cells as previously
described (McGregor and Schleiss, 2001). Rescue was conﬁrmed by
PCR analysis using common ﬂanking gene primers for GP84 (GPCMV)
or UL84 (HCMV) as described previously.
GPCMV multi-step growth curve and HCMV one step growth curve
GPCMV infection was performed on six well dishes as previously
described (McGregor and Schleiss, 2001) except that the input virus
(moi) was 0.1 pfu/cell per well. Virus time samples were harvested
immediately after 1 h virus adsorption (day 0) and every 24 h (days
1–7). Samples were harvested, stored at−80 °C and titrated after the
ﬁnal time point had been harvested as previously described. For
HCMV a one step growth curve was performed on conﬂuent
monolayers of HFF cells in 6 well dishes with an input virus moi of
3 pfu/cell. One step growth curve was performed as previously
described (McGregor and Schleiss, 2001). Virus time samples were
taken every 12 h from 0 to 96 h post infection. Time samples were
stored at −80 °C and titrated after the ﬁnal time point had been
harvested.
Immunoﬂuorescence and Western blot analysis
Immunoﬂuorescence assays were performed on full length and
truncated GP84 proteins transiently expressed in GPL cells by
transfection of GP84 FLAG-tagged expression plasmids pFLAGGP84,
pFLAGGP84(B), pFLAGGP84(S) and pFLAGGP84(BS). Assay was
performed as previously described on GPL cover slips in six well
dishes (McGregor et al., 2004) except that samples were ﬁxed in
−20 °C methanol at various time points post transfection (3, 5, 6, 8,
12, 18, 24, 36 and 48 h post transfection). The mouse anti-FLAG
antibody (Sigma) was used at 1/1000 dilution and the secondary
antibody anti-mouse IgG (Sigma) conjugated to FITC was used at 1/
1000 dilution. For co-localization study of plasmid based transient
expression of GFP tagged GP84 (pGFPGP84) and FLAG-tagged GP44
(pFLAGGP44) plasmid transfections were performed as described
above but cells were ﬁxed with 4% paraformaldehyde for 5 min to
maintain GFP ﬂuorescence and post ﬁxation treated with 0.2% Triton
X-100 to increase cell membrane permeability. Immunoﬂuorescence
assay was performed as described above except the secondary
antibody was anti-mouse IgG conjugated to Texas red (Santa Cruz
Biotech.) at 1/200 dilution. Cells were also counterstained with DAPI
(Vector labs) to identify the cell nucleus. Co-localization experi-
ments were harvested at 12h. post transfection to enable optimal
detection of Texas red (conjugated to secondary antibody) tagged
GP44 protein.
Western blot was carried out as previously described (Schleiss
et al., 1999) except that the primary antibody was mouse anti-FLAG
(1/1,000 dilution) and the secondary was anti-mouse IgG conjugated
to horseradish peroxidase (Santa Cruz Biotech.) used at a 1:10,000
dilution followed by detection by chemiluminescence using ECL
substrate (Amersham) following the manufacturer's protocol.
Generation of GPL cell lines expressing GFP or GFP-GP84ID
A PCR cassette was generated that contained the minimal
transdominant inhibitory domain for GP84 identiﬁed in the
86 A. McGregor et al. / Virology 410 (2011) 76–87expression vector pFLAGGP84(BS) plus additional ﬂanking sequence
(codons 170–309). The PCR product was cloned as a Bgl II fragment in
frame into the C-terminal domain of GFP expression plasmid pEGFPC-
1 (Clontech) cut with Bgl II to generate pGFPGP84ID as described in
plasmid constructs section. This plasmid expressed GFP under HCMV
IE enhancer control but also encoded a neomycin drug resistance
cassette under SV40 promoter control to allow selection of G418
(Invitrogen) antibiotic resistant mammalian cells. Plasmids pEGFP-C1
and pGFPGP84ID were separately transfected onto GPL cells in six
well dishes (4 μg per well) as previously described (McGregor et al.,
2004). At 36–48 h post transfection the F-12 media was replaced with
media containing G418 at a concentration of 600 μg/ml and the media
was changed every two days for the ﬁrst 7–10 days. At that stage the
G418 concentration was dropped to 500 μg/ml and the media
changed every three days. Resistant colonies of cells were detected
by about 18–24 days post transfection. GFP positive colonies were
detected using an inverted microscope equipped for GFP ﬂuorescent
imaging. Between days 30 and 40, well separated, GFP positive cell
colonies were individually isolated using cloning rings and transferred
to 25 cm2 ﬂasks and expanded as cell lines. 10 cell lines were
generated for each plasmid. 6 out of the 10 GFP cell lines maintained a
strong level of GFP through multiple cell passages but only 3 out of 10
GFPGP84ID cell lines maintained consistent levels of GFP under
multiple cell passages. Cells were maintained under G418 selection
under passage in tissue culture (300 μg/ml). One GFP cell line per
plasmid was selected for use in transdominant inhibitory growth
assays.
Transdominant inhibitory growth assays
GPCMV BAC and GP84 expression plasmid transient inhibitory growth
assay
Six well dishes of conﬂuent monolayers of GPL cells were
transfected with different combinations of GPCMV BAC DNA (1 μg)
and GP84 FLAG tag expression vectors (4 μg). The different combina-
tions were GPCMV BAC alone or plus: (1) pFLAGGP84; (2) pFLAGGP84
(B); (3) pFLAGGP84(S); (4) pFLAGGP84(BS); and (5) pTAG2A (empty
vector). Plates were transfected as previously described (McGregor
et al., 2004). Assays were followed by GFP reporter gene expression
for identiﬁcation of GFP positive GPCMV BAC transfected cells and
GFP viral spread across the cell monolayer. Assays were extended to
day 18 where virus stocks were harvested and titrated out on GPL
cells. Individual assays were repeated multiple times.
GPCMV transdominant inhibitory growth assay on GFP and GFPGP84ID
GPL cells
Clonal transformed GPL cells expressing GFP or GFPGP84ID (the
minimal inhibitory domain fromGP84 fused to the C-terminal domain
of GFP) were used to seed six well dishes. Conﬂuent monolayers were
tested for their ability to support virus replication at different moi of
GPCMV (vAM403), where moi was 0.1, 0.01 or 0.001 pfu/cell. Virus
infections were carried out in duplicate wells and allowed to progress
for 5 days at which time the wells were harvested and the viral titers
determined by titration on regular GPL cells. Herpes simplex virus
(type 1) at a moi 0.001 pfu/cell was used to infect both GFP and
GFPGP84ID cells as an additional control to demonstrate speciﬁcity of
the GP84 transdominant inhibitory growth effect to GPCMV.
RT-PCR GP84 expression
RT-PCR was performed as previously described (McGregor et al.,
2008). The GP84 gene expression in ATCC wild type GPCMV infected
GPL cells (inputmoi 1 pfu/cell)was determined using primers FGP84RT
(5′ CTACGGCTTCATCAAGATG) and RGP84RT (5′ CATCGCGTCCTGGAT-
GAAGTAC). Control cellular gene expression was for GAPDH as
previously described (McGregor et al., 2008). IE2 (GP122) geneexpression was determined using RT-PCR primers FGP122RT 5′
GACATGGAGCGCCGGTAGCG and RGP122RT 5′CATGGCAGACCTGATGC-
GAC. The viral DNA polymerase gene (GP54) was assayed by primer set
FGP54RT 5′GAGACGGAGGACGTTACTAAG and RGP54RT 5′CTCACAATC-
TATCTCGATGTC. For speciﬁc selection of IE transcripts only, cells were
treatedwith cycloheximide (100 μg/ml) 1 h. prior to virus infection and
for 4 h. post infection at which point the cells were harvested and RNA
extracted for analysis. For exclusion of late gene transcripts, phospho-
noacetic acid (PAA) was present (200 μg/ml) as previously described
Schleiss et al. (1999) and cell monolayers were harvested at 12 h. post
infection for RNA extraction and analysis.
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